We hope that this combination
will allow us to see more complete responses in patients with difficult to treat diseases, like
the one seen in the Phase 1A study that has resulted in complete tumour eradication for
more than 15 months now.”
Combination therapy is the way to go in this field, and this NK platform can be combined in endless ways.
Heaps of shots on goal coming up, and if just one hits the back of the net, we are of and running.
This stock is ridiculously cheap with the platforms it has and the amount of combinations it will be taking to clinic.
I certainly will be buying more here when funds come available.
- Forums
- ASX - By Stock
- CHM
- Ann: First phase 1B trial of NK cells with IL-2 & Vactosertib
Ann: First phase 1B trial of NK cells with IL-2 & Vactosertib, page-3
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
|
|||||
Last
1.9¢ |
Change
0.001(5.56%) |
Mkt cap ! $16.64M |
Open | High | Low | Value | Volume |
1.9¢ | 1.9¢ | 1.8¢ | $20.08K | 1.065M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 1573568 | 1.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.9¢ | 78200 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 1573568 | 0.018 |
8 | 1203647 | 0.017 |
15 | 3283229 | 0.016 |
8 | 1470232 | 0.015 |
3 | 2071001 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.019 | 78200 | 2 |
0.020 | 1462067 | 5 |
0.021 | 555110 | 3 |
0.022 | 560000 | 3 |
0.023 | 155000 | 2 |
Last trade - 16.10pm 02/07/2024 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |